BioCentury
ARTICLE | Clinical News

Saphris asenapine regulatory update

March 30, 2015 7:00 AM UTC

FDA approved Saphris asenapine from Merck to treat manic or mixed episodes associated with bipolar I disorder in patients ages 10-17. Saphris is already approved in the U.S. to treat manic or mixed ep...